Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors
Harvard Apparatus Regenerative Technology (OTCQB: HRGN) has appointed Mao Zhang as an independent director to its Board of Directors. Zhang, the Founder and CEO of StellarS Capital, brings over 15 years of experience in financial markets, including hedge fund and private equity expertise. This appointment aims to strengthen the company's business innovation, strategy, and finance areas.
Jerry He, chairman of Harvard Apparatus Regenerative Technology, expressed confidence that Zhang's deep business and investment experience will be instrumental in pursuing the company's mission to address unmet patient needs. Zhang, in turn, stated his enthusiasm for joining the board at this important stage of clinical development, highlighting the company's potential to develop novel cell therapies that could change and extend patients' lives through regenerated organs.
Harvard Apparatus Regenerative Technology (OTCQB: HRGN) ha nominato Mao Zhang come direttore indipendente del suo Consiglio di Amministrazione. Zhang, fondatore e CEO di StellarS Capital, porta con sé oltre 15 anni di esperienza nei mercati finanziari, inclusa una solida competenza in hedge fund e private equity. Questa nomina mira a rafforzare l'innovazione aziendale, la strategia e le aree finanziarie dell'azienda.
Jerry He, presidente di Harvard Apparatus Regenerative Technology, ha espresso fiducia nel fatto che la profonda esperienza di Zhang in ambito commerciale e negli investimenti sarà fondamentale per perseguire la missione dell'azienda di soddisfare i bisogni insoddisfatti dei pazienti. Zhang, a sua volta, ha dichiarato il suo entusiasmo per l'ingresso nel consiglio in questa fase cruciale dello sviluppo clinico, evidenziando il potenziale dell'azienda di sviluppare nuove terapie cellulari che potrebbero cambiare e prolungare la vita dei pazienti attraverso organi rigenerati.
Harvard Apparatus Regenerative Technology (OTCQB: HRGN) ha nombrado a Mao Zhang como director independiente de su Junta Directiva. Zhang, fundador y CEO de StellarS Capital, aporta más de 15 años de experiencia en los mercados financieros, incluida la experiencia en fondos de cobertura y capital privado. Esta nombramiento tiene como objetivo fortalecer la innovación empresarial, la estrategia y las áreas financieras de la empresa.
Jerry He, presidente de Harvard Apparatus Regenerative Technology, expresó su confianza en que la profunda experiencia empresarial e inversora de Zhang será fundamental para perseguir la misión de la empresa de abordar las necesidades insatisfechas de los pacientes. Zhang, a su vez, declaró su entusiasmo por unirse a la junta en esta etapa importante del desarrollo clínico, destacando el potencial de la empresa para desarrollar nuevas terapias celulares que podrían cambiar y prolongar la vida de los pacientes a través de órganos regenerados.
하버드 장치 재생 기술(OTCQB: HRGN)은 마오 장을 독립 이사로 임명했습니다. 장은 StellarS Capital의 창립자이자 CEO로, 헤지펀드 및 사모펀드에 대한 전문 지식을 포함하여 금융 시장에서 15년 이상의 경험을 가지고 있습니다. 이 임명은 회사의 비즈니스 혁신, 전략 및 재무 분야를 강화하는 것을 목표로 하고 있습니다.
하버드 장치 재생 기술의 회장 제리 허는 장의 깊은 비즈니스 및 투자 경험이 회사의 미션인 환자의 충족되지 않은 요구를 해결하는 데 중요한 역할을 할 것이라는 확신을 표명했습니다. 장은 또한 이 임상 개발의 중요한 단계에서 이사회에 합류하게 된 것에 대해 열정을 표현하며, 회사가 환자의 삶을 변화시키고 연장할 수 있는 혁신적인 세포 치료제를 개발할 수 있는 잠재력을 강조했습니다.
Harvard Apparatus Regenerative Technology (OTCQB: HRGN) a nommé Mao Zhang comme administrateur indépendant de son Conseil d'Administration. Zhang, fondateur et CEO de StellarS Capital, apporte plus de 15 ans d'expérience dans les marchés financiers, y compris une expertise en fonds spéculatifs et en capital-investissement. Cette nomination vise à renforcer l'innovation, la stratégie et les domaines financiers de l'entreprise.
Jerry He, président de Harvard Apparatus Regenerative Technology, a exprimé sa confiance dans le fait que la profonde expérience commerciale et d'investissement de Zhang sera déterminante pour poursuivre la mission de l'entreprise qui est de répondre aux besoins non satisfaits des patients. Zhang, de son côté, a déclaré son enthousiasme à rejoindre le conseil à cette étape importante du développement clinique, soulignant le potentiel de l'entreprise à développer de nouvelles thérapies cellulaires pouvant changer et prolonger la vie des patients grâce à des organes régénérés.
Harvard Apparatus Regenerative Technology (OTCQB: HRGN) hat Mao Zhang als unabhängiges Mitglied in seinen Aufsichtsrat berufen. Zhang, der Gründer und CEO von StellarS Capital, bringt über 15 Jahre Erfahrung in den Finanzmärkten mit, einschließlich Fachwissen in Hedgefonds und Private Equity. Diese Ernennung zielt darauf ab, die Innovations-, Strategie- und Finanzbereich des Unternehmens zu stärken.
Jerry He, Vorsitzender von Harvard Apparatus Regenerative Technology, äußerte sich zuversichtlich, dass Zhangs umfassende geschäftliche und investive Erfahrung entscheidend sein wird, um die Mission des Unternehmens zu verfolgen, den unerfüllten Bedarf der Patienten zu decken. Zhang seinerseits erklärte, dass er sich in dieser wichtigen Phase der klinischen Entwicklung sehr freut, dem Vorstand beizutreten, und hob das Potenzial des Unternehmens hervor, neuartige Zelltherapien zu entwickeln, die das Leben der Patienten durch regenerierte Organe verändern und verlängern könnten.
- Appointment of Mao Zhang as an independent director with extensive financial market experience
- Addition of expertise in business innovation, strategy, and finance to the board
- Potential for improved financial and strategic guidance during a period of growth
- None.
Holliston, MA, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage biotechnology company developing the technology to regenerate organs inside the body to treat severe diseases, today announced the appointment of Mao Zhang as an independent director to its Board of Directors, adding strength in the areas of business innovation, strategy and finance.
Mr. Mao Zhang is the Founder and Chief Executive Officer of StellarS Capital, a multi-billion-dollar alternative asset management firm established in 2016. He has over 15 years of experience in financial markets including hedge fund and private equity. He began his career with Magnetar Capital in 2007, leading its Asian business. He holds a Bachelor of Science degree from the University of Pennsylvania.
"We are pleased to welcome Mao Zhang to the Harvard Apparatus Regenerative Technology Board," said Jerry He, chairman of Harvard Apparatus Regenerative Technology, "Mao's deep business and investment experience will be instrumental in helping the company to pursue the mission to serve the unmet patient needs. His appointment will be invaluable to Harvard Apparatus Regenerative Technology at a time of significant opportunity and growth."
Mr. Zhang commented, "I am very pleased to be joining the Board of Directors for Harvard Apparatus Regenerative Technology at this exciting stage of its clinical development. Harvard Apparatus Regenerative Technology is developing promising novel cell therapies with the potential to change and extend the lives of patients with regenerated organs. I look forward to helping Harvard Apparatus Regenerative Technology reach its financial and strategic objectives."
About Harvard Apparatus Regenerative Technology, Inc.
We are a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma or birth defects. Our technology is based on our proprietary cell-therapy platform that uses a patient’s own stem cells to regenerate and restore function to damaged organs. We believe that our technology represents a next-generation solution for restoring organ function because it allows the patient to regenerate their own organ, thus eliminating the need for human donor or animal transplants, the sacrifice of another of the patient’s own organs or permanent artificial implants.
We conducted the world’s first successful regeneration of the esophagus in a patient with esophageal cancer in August 2017. This surgery was performed by Dr. Dennis Wigle, Chair of Thoracic Surgery at the Mayo Clinic. The results were published in the Journal of Thoracic Oncology Clinical and Research Reports in August 2021. The procedure demonstrated that our technology was able to successfully regenerate esophageal tissue, including the mucosal lining, to restore the integrity, continuity and functionality of the esophageal tube.
HRGN has 15 issued U.S. patents, 2 issued in China, 1 issued in Japan, 2 issued in Europe, 2 U.S. orphan-drug designations which can provide seven years of market exclusivity in the US market after market approval from the FDA and 1 EMA orphan drug designation, which can provide ten years of market exclusivity in the European market after market approval from the EMA.
For more information, please visit www.hregen.com and connect with the Company on LinkedIn.
Forward-Looking Statements
Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements in this press release include, but are not limited to, statements relating to the capabilities and performance of our products and product candidates; development expectations and regulatory approval of any of the Company’s products, by the U.S. Food and Drug Administration, the European Medicines Agency or otherwise, which expectations or approvals may not be achieved or obtained on a timely basis or at all; and success with respect to any collaborations, clinical trials and other development and commercialization efforts of the Company’s products, which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the Company’s inability to obtain needed funds in the immediate future; the Company's ability to obtain and maintain regulatory approval for its products; plus other factors described under the heading “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 or described in the Company’s other public filings. The Company’s results may also be affected by factors of which the Company is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.
Investor Relations Contact
Joseph Damasio
Chief Financial Officer
774-233-7330
jdamasio@hregen.com
FAQ
Who is the new board member appointed to Harvard Apparatus Regenerative Technology (HRGN)?
What expertise does Mao Zhang bring to Harvard Apparatus Regenerative Technology's (HRGN) board?
When was Mao Zhang appointed to the board of Harvard Apparatus Regenerative Technology (HRGN)?
What is Harvard Apparatus Regenerative Technology (HRGN) developing?
